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Summary. Aims: The extent to which hemostatic and inﬂam-
matory biomarkers are related to angina pectoris as compared
with myocardial infarction (MI) remains uncertain. We
examined the relationship between a wide range of inﬂamma-
tory andhemostatic biomarkers, includingmarkers of activated
coagulation, ﬁbrinolysis and endothelial dysfunction and
viscosity, with incident myocardial infarction (MI) or coronary
heart disease (CHD) death and incident angina pectoris
uncomplicated by MI or CHD death in older men. Methods:
A prospective study of 3217 men aged 60–79 years with no
baseline CHD (angina or MI) and who were not on warfarin,
followed up for 7 years during which there were 198 MI/CHD
death cases and 220 incident uncomplicated angina cases.
Results: Inﬂammatory biomarkers [C-reactive protein (CRP),
interleukin-6, ﬁbrinogen], plasma viscosity and hemostatic
biomarkers [vonWillebrand factor (VWF) and ﬁbrin D-dimer]
were associated with a signiﬁcant increased risk of MI/CHD
death but not with uncomplicated angina even after adjustment
for age and conventional risk factors. Adjustment for CRP
attenuated the relationships between VWF, ﬁbrin D-dimer and
plasma viscosity with MI/CHD death. Comparisons of diﬀer-
ing associations with risk of MI/CHD deaths and uncompli-
cated angina were signiﬁcant for the inﬂammatory markers
(P < 0.05) and marginally signiﬁcant for ﬁbrin D-dimer
(P = 0.05). In contrast, established risk factors including
blood pressure and high-density lipoprotein (HDL)-cholesterol
were associated with both MI/CHD death and uncomplicated
angina. Conclusion: Circulating biomarkers of inﬂammation
andhemostasis are associatedwith incidentMI/CHDdeath but
not incident angina uncomplicated by MI or CHD death in
older men.
Keywords: angina pectoris, coronary heart disease, hemostasis,
inﬂammation, myocardial infarction.
Introduction
It is well established that inﬂammation plays a major role in the
development and progression of atherosclerosis, including
plaque rupture which initiates coronary thrombosis and
myocardial infarction (MI) [1]. Activated coagulation, endo-
thelial dysfunction and ﬁbrinolysis have also been associated
with risk of coronary heart disease (CHD) [2–13]. The term
CHDcovers all forms of atherosclerotic disease of the coronary
arteries with MI/coronary death as the most serious manifes-
tation and with angina (unstable or stable) as a speciﬁc
symptom complex indicating myocardial ischemia. Many
persons develop only stable angina, with chest pain consistently
related to physical exertion or emotional stress. Many
prospective studies have shown independent associations
between CHD events (MI and CHD death) and C-reactive
protein (CRP), interleukin-6 (IL-6), ﬁbrinogen, vonWillebrand
factor (VWF), ﬁbrin D-dimer and tissue plasminogen activator
antigen (t-PA) in both middle-aged and older populations [2–
13]. In contrast, information on the association of these
circulating biomarkers with the risk of uncomplicated angina
events is limited.
The major pathophysiological difference distinguishing MI
and other acute coronary syndromes from uncomplicated
stable angina pectoris is the rupture of an atherosclerotic
plaque with subsequent thrombosis formation which causes
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acute coronary events [1,14]. Some studies (mainly observa-
tional in nature) have addressed the question of whether the
biological proﬁle of those who develop MI/coronary death
may be different from those who have uncomplicated angina
[15–19]. Conventional CHD risk factors such as blood lipids,
blood pressure and smoking have been shown to predict both
MI and angina [20,21]. Few prospective studies have examined
whether the relationships of inﬂammatory and hemostatic
biomarkers to angina andMI differ but there is suggestion that
many of these factors related to MI including inﬂammatory
markers, endothelial dysfunction and ﬁbrynolytic activity are
not related to angina [8–10]. However, in a recent nested case–
control study of middle-aged men (PRIME Study) inﬂamma-
tory but not hemostatic factors predicted stable angina [11].
Whether these ﬁndings apply to older men is not known. We
hypothesized that the relationship between inﬂammatory and
hemostatic biomarkers including CRP, IL-6 plasma viscosity
and several markers of activated coagulation, ﬁbrinolysis and
endothelial dysfunction [ﬁbrinogen; coagulation factors VII,
VIII, and IX; ﬁbrin D-dimer, t-PA antigen, VWF activated
partial thromboplastin time (APTT) and activated protein C
(APC) ratio] differed between older men aged 60–79 years who
develop (i) incident MI or CHD death and (ii) incident stable
angina, uncomplicated by MI or CHD death.
Subjects and methods
The British Regional Heart Study is a prospective study of
cardiovascular disease involving 7735 men aged 40–59 years
drawn from general practice in each of 24 British towns, who
were screened between 1978 and 1980 [22]. The population
studied was socio-economically representative of British men
but consisted almost entirely of white Europeans (> 99%). In
1998–2000, all surviving men, now aged 60–79 years (mean age
68.7 years), were invited for a 20th year follow-up examination.
The men completed a questionnaire which included questions
on their medical history and lifestyle behavior. They were
requested to fast for a minimum of 6 h, during which time they
were instructed to drink only water and to attend for
measurement at a pre-speciﬁed time between 08:00 and
18:00 hours. All men were asked to provide a blood sample,
collected using the Sarstedt Monovette system. Four thousand
two hundred and ﬁfty-twomen (77%of survivors) attended for
examination. Four thousand and eighty-eight men had at least
one hemostatic/inﬂammatory marker measured. We further
excluded men with a recall of a diagnosis of CHD (myocardial
infarction or angina) (n = 793) andmen on warfarin (n = 78)
leaving 3217 men for analysis.
Cardiovascular risk factors
Anthropometric measurements including body weight, height
and waist circumference (WC) were carried out. Details of
measurements and classiﬁcation methods for smoking status,
physical activity, body mass index, WC, social class, blood
pressure, high-density lipoprotein (HDL)-cholesterol, triglyce-
rides and glucose have been described [23,24]. Men with a
doctor diagnosis of diabetes or those with a fasting glucose of
‡ 7 mmol L)1 (WHO criteria) were considered to have
prevalent diabetes.
Hemostatic and inflammatory biomarkers
At the 20-year examination, blood was anticoagulated with K2
EDTA (1.5 mg mL)1) for measurement of plasma viscosity at
37 C in a semi-automated capillary viscometer (Coulter Elec-
tronics, High Wycombe, UK). Blood was also anticoagulated
with 0.109 M trisodium citrate (9:1 v:v) for measurement of
clottable ﬁbrinogen (Clauss method); as well as coagulation
factors (F)VII, VIII and IX; activated partial thromboplastin
time (APTT) and activated proteinC (APC) ratio (measured by
theAPTT-basedmethod) inanMDA-180 coagulometer (Orga-
nonTeknika,Cambridge,UK).Plasmalevelsoft-PAantigenand
D-dimer were measured with enzyme-linked immunosorbent
assays (ELISA) (Biopool AB, Umea, Sweden) as was VWF
antigen (Dako,HighWycombe,UK).C-reactiveprotein (CRP)
was assayed by ultra-sensitive nephelometry (Dade Behring,
Milton Keynes, UK). IL-6 was assayed using a high-sensitivity
ELISA(R&DSystems,Oxford,UK).Theinter-assaycoefﬁcient
ofvariation(CV)forthebiomarkersrangedfrom< 1%(plasma
viscosity) to 8.9% (IL6) and the intra-assay CV ranged from<
1%(plasmaviscosity)to8.4%(APCratio).Inter-andintra-assay
CVforIL-6was8.9%and7.5%,8.3%and4.7%forCRP,3.7%
and2.6%forﬁbrinogenand5.2%and4.7%forﬁbrinD-dimer.
Follow-up
All men have been followed up from initial examination (1978–
1980) to June 2006 for all cause mortality and cardiovascular
morbidity and follow-up has been achieved for 99% of the
cohort [25]. In the present analyses, all morbidity follow-up is
based on follow-up from re-screening in 1998–2000 atmean age
60–79 years, a mean follow-up period of 7 years (range 6–
8 years). Information on death was collected through the
established tagging procedures provided by the National
Health Service registers. Fatal coronary heart disease events
were deﬁned as death with coronary heart disease (ICD codes
410–414) as the underlying code. Evidence regarding non-fatal
MI and angina was obtained by reports from general practitio-
ners supplemented by regular 2-yearly reviews of the patients
practice records (including hospital and clinic correspondence)
carriedout through to theendof the studyperiod.Diagnosisofa
non-fatal MI was conﬁrmed in accordance with World Health
Organisation criteria, on the basis of two of the following (i)
severe chest pain, (ii) increased levels of cardiac enzymes and (iii)
electrocardiography (ECG) changes consistent with MI. Diag-
nosisofuncomplicatedangina refers to thedevelopmentof chest
pain related to exertion or stress, and not superseded by the
development of MI or CHD death. Men who developed both
anginaandMI(orCHDdeath) (n = 32)wereclassiﬁedasbeing
in the latter group. Thus, the two outcome measures (uncom-
plicated angina andMI/CHD death) are mutually exclusive.
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Statistical methods
Analyses are based on the division of hemostatic and inﬂam-
matory markers into equal thirds. Coxs proportional hazards
model was used to assess the multivariate-adjusted relative risk
for the highest third compared with the lowest third (reference
group). In the adjustment, smoking [never, long term
ex-smokers (> 15 years), recent ex-smokers and current
smokers], social class (7 groups), physical activity (4 groups),
alcohol intake (5 groups), pre-existing diabetes (yes/no) and
stroke (yes/no) were ﬁtted as categorical variables. BMI,
systolic blood pressure and HDL-C were ﬁtted as continuous
variables. Tests for trends were carried out ﬁtting the hemo-
static and inﬂammatory markers in its original continuous
form. Differences for associations between the risk factor of
interest and MI/CHD deaths and uncomplicated angina were
evaluated using likelihood ratio tests based on methods of
competing risk survival analysis as described by Glynn and
Rosner [26]. The likelihood ratio tests evaluated the hypothesis
that the associations of risk factors were the same forMI/CHD
deaths and uncomplicated angina. We had 90% power to
detect a mean difference of 0.19 in log CRP between men with
angina and men with MI.
Results
During the mean follow-up period of 7 years, there were 198
MI or CHD death events and 220 new diagnoses of uncom-
Table 1 Age-adjusted distributions of baseline characteristics and age-adjusted mean levels of cardiovascular risk factors and inflammatory/hemostatic
biomarkers according to CHD status at follow-up (none, angina only, or MI/CHD death)
CHD status
None
(n = 2809)
Angina only
(n = 220)
P-value for diﬀerence
Comparison with none
MI/CHD death
(n = 198)
P-value for diﬀerence
Comparison with none
% Current smokers 12.5 12.6 0.98 21.2 0.0002
% Physically inactive 9.1 10.7 0.37 13.6 0.07
% Manual occupation 52.3 54.8 0.46 58.3 0.11
% Light/moderate drinkers 40.5 42.7 0.57 38.2 0.18
% Diabetes 10.2 11.2 0.62 19.2 0.0001
% Stroke 4.1 5.6 0.21 6.7 0.21
Waist circumference (cm) 96.9 97.5 0.57 97.3 0.59
BMI (kg m)2) 26.8 27.1 0.40 26.9 0.54
SBP (mmHg) 149.6 153.3 0.02 157.2 < 0.0001
Cholesterol (mmol L)1) 6.06 6.21 0.04 6.13 0.32
HDL-C (mmol L)1) 1.35 1.26 0.002 1.25 < 0.0001
Triglyceride (mmol L ) 1.60 1.77 0.006 1.73 0.01
Inﬂammatory and hemostatic markers
CRP (g L)1) 1.63 1.68 0.66 2.22 < 0.0001
IL6 (pg mL)1) 2.36 2.41 0.59 2.89 < 0.0001
Fibrinogen (g L)1) 3.23 3.23 0.94 3.42 < 0.0001
VWF (IU dL)1) 137.1 137.7 0.87 146.4 0.005
t-PA (ng mL)1) 10.81 10.95 0.65 11.45 0.05
D-dimer (ng mL)1) 79.8 79.8 0.91 95.6 0.002
Factor VII (IU dL)1) 117.7 118.3 0.77 119.6 0.31
Factor VIII (IU dL)1) 131.0 131.5 0.79 135.2 0.07
Factor IX (IU dL)1) 131.1 133.5 0.16 135.7 0.01
Plasma viscosity (mPa.s) 1.281 1.289 0.14 1.301 0.0006
APTT(s) 34.2 34.2 0.86 34.3 0.89
APC ratio 3.21 3.23 0.21 3.26 0.35
CHD, coronary heart disease; MI, myocardial infarction; BMI, body mass index; SBP, systolic blood pressure; HDL-C, high-density lipoprotein
cholesterol; CRP, C-reactive protein; VWF, von Willebrand factor.
Table 2 Established cardiovascular risk factors and adjusted relative risk (95% CI) of developing angina versus MI/CHD death
Angina only MI/CHD death
Age-adjusted Model 1 Age Model 1
Physical inactivity (mod-vig/vig vs. inactive) 0.98 (0.65, 1.46) 1.23 (0.80, 1.88) 0.63 (0.40, 0.99) 0.80 (0.50, 1.28)
Current smoking 1.15 (0.74, 1.78) 1.02 (0.64, 1.64) 2.19 (1.46, 3.23) 1.89 (1.22, 2.91)
SBP (mmHg) (T3 vs. T1; ‡ 159.5 vs. < 139.4) 1.46 (1.07, 2.01) 1.43 (1.03, 1.99) 1.90 (1.32, 2.73) 1.76 (1.20, 2.57)
HDL (mmol L)1) (T3 vs. T1; ‡ 1.5 vs. < 1.2) 0.59 (0.22, 0.84) 0.59 (0.38, 0.93) 0.52 (0.36, 0.74) 0.57 (0.39, 0.84)
Diabetes 1.08 (0.72, 1.62) 0.89 (0.57, 1.40) 2.10 (1.49, 2.97) 1.91 (1.32, 2.77)
Cholesterol (mmol L)1) (T3 vs. T1; ‡ 6.5 vs. < 5.6) 1.50 (1.07, 2.10) 1.73 (1.19, 2.53) 1.19 (0.85, 1.68) 1.38 (0.93, 2.04)
Triglyceride (mmol L)1) (T3 vs. T1; ‡ 1.96 vs. < 1.28) 1.30 (0.93, 1.82) 0.77 (0.50, 1.17) 1.84 (1.28, 2.63) 1.32 (0.83, 2.08)
T3 vs. T1: top third vs. bottom third. Model 1: adjusted for age, social class, alcohol intake, BMI, prevalent stroke, and each of the other factors in
the Table. CHD, coronary heart disease; MI, myocardial infarction.
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plicated angina (with no MI or CHD death) in the 3217 men
with no prevalent CHD baseline.
Table 1 shows the age-adjusted baseline characteristics in the
men who developed angina only, those who developed MI/
CHDdeath, and inmen who remained free of CHD. Smoking,
diabetes and physical inactivity were associated with MI/CHD
death but not with uncomplicated angina. Total blood
cholesterol was signiﬁcantly higher in men with angina and
was also higher in men with MI/CHD death but the difference
was not statistically signiﬁcant compared with those with no
CHD. Systolic blood pressure, HDL-cholesterol and triglyce-
rides were associated with both outcomes; no signiﬁcant
associations were seen with WC, BMI, alcohol intake or social
class. Inﬂammatory biomarkers (CRP, IL-6, ﬁbrinogen),
plasma viscosity, endothelial dysfunction markers (VWF,
t-PA), and coagulation factors (VIII and IX, but not VII)
were signiﬁcantly higher in cases of MI/CHD death, but not in
cases of incident angina compared with those who were CHD
event free. No association was seen with APTT or APC ratio.
Table 2 shows the relative risk of CHD for the traditional
CVD risk factors shown to be associated with either MI/CHD
death or angina in age-adjusted analyses and then with
additional adjustment for lifestyle factors (age, social class,
smoking, physical activity, alcohol intake) and blood lipids
(HDL-C, triglyceride and cholesterol) and systolic blood
pressure. Blood lipids (HDL-C and cholesterol but not
triglycerides) and systolic blood pressure remained signiﬁcantly
associated with incident angina after adjustment. Current
smoking, diabetes, HDL-C and systolic blood pressure
remained signiﬁcantly associated with MI/CHD death after
adjustment. No signiﬁcant independent association was seen
between physical activity or triglycerides and CHD events.
Table 3 shows the age-adjusted relative risk of angina and
MI/CHD death for men in the top third of the distribution of
each inﬂammatory or hemostatic biomarker compared with
men in the lowest third. Only factors shown to be associated
with MI/CHD death in age-adjusted analyses are shown.
No associations were seen in men with angina only. Inﬂam-
matory biomarkers (CRP, IL-6, ﬁbrinogen), plasma viscosity,
D-dimer and VWF (but not t-PA or factor IX) remained
signiﬁcantly associated with MI/CHD death after adjustment
for age, smoking, BMI, physical activity, alcohol intake,
systolic blood pressure, HDL-cholesterol, history of diabetes
and stroke.
To allow the strengths of associations betweenMI/death and
the individual risk factors to be compared, and to contrast the
relationships with MI/CHD death and with angina, Table 4
shows the adjusted hazards ratio for MI/CHD death and for
angina for a 1 SD increment in systolic blood pressure and
HDL-C and the biomarkers shown to be independently
associated with MI/CHD death in Table 3. Systolic blood
pressure and HDL-C were both associated with risk of MI/
CHD death and angina, in contrast to the inﬂammatory and
hemostatic biomarkers which were only associated with MI/
CHD death. Comparisons of differing association between the
two endpoints showed signiﬁcant/marginally signiﬁcant differ- T
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ences in the relationships between the inﬂammatory biomar-
kers (CRP, IL-6, ﬁbrinogen), ﬁbrin D-dimer and MI/CHD
death and uncomplicated angina. Among the inﬂammatory
and hemostatic biomarkers the magnitude of association with
MI/CHDdeath appeared to be greatest for CRP and IL-6. The
associations between ﬁbrin D-dimer, VWF or plasma viscosity
andMI/CHD death were attenuated after adjustment for CRP
(Table 4). In contrast, the association between systolic blood
pressure and HDL-C with MI/CHD remained after adjust-
ment for CRP. As IL-6 and ﬁbrinogen both reﬂect markers of
inﬂammation, adjustments were not made for CRP for these
variables.
Discussion
In this prospective study of British men aged 60–79 years
without baseline evidence of CHD, we have conﬁrmed the
results of previous studies [2–13] that circulating biomarkers of
inﬂammation, endothelial dysfunction, coagulation and ﬁbri-
nolysis (CRP, IL-6, ﬁbrinogen, plasma viscosity, VWF and
ﬁbrinD-dimer) are associated with risk of incident major CHD
events (MI or CHD death), after adjustment for traditional
CHD risk factors. In contrast, we have also shown that this
proﬁle of circulating biomarkers was not associated with risk of
new angina pectoris, uncomplicated by MI or CHD death.
Our ﬁndings are consistent with limited published evidence
from previous cross-sectional [16], case–control [17] and
prospective [8–10] studies which have shown no association
between inﬂammatory or hemostatic biomarkers with angina.
However, in the recent report from the PRIME Study (a nested
case–control prospective study of men aged 40–59 years),
inﬂammatory markers were predictive of both acute coronary
syndrome and stable angina but hemostatic markers in
particular VWF plasma levels were higher in individuals who
subsequently developedMI (fatal or non-fatal) but not in those
who develop angina pectoris [11]. The differences in ﬁnding
between the associations of inﬂammatory biomarkers and
stable angina in the PRIME Study and the present study of
older men may relate to the age differences in the two
populations. With over 200 cases of incident uncomplicated
stable angina, and 200 cases of incident MI/CHD death,
among 3200 men followed for a mean of 7 years, the present
study signiﬁcantly and prospectively extends the previous
literature comparing the associations of these different CHD
outcomes with circulating levels of inﬂammatory and hemo-
static biomarkers.
The evidence from this and previous studies suggests that
circulating biomarkers of inﬂammation [9,16,17], endothelial
dysfunction, coagulation and ﬁbrinolysis [8,10,15,17] may be
speciﬁcally related to acute plaque rupture and thrombosis (the
pathophysiological basis of MI and CHD death) [1,14] rather
than to slowly progressive occlusive coronary atherosclerosis
which (sometimes with coronary artery spasm) is the patho-
physiological substrate of uncomplicated stable angina. This
suggestion is consistent with evidence that suppression of
inﬂammation [27,28], coagulation [29] and thrombolysis [30]
each plays a key role in treatment of acute coronary artery
syndromes after plaque rupture. Such processes may poten-
tially be less important in development of uncomplicated stable
angina (or, in the arteries supplying the lower limb, uncom-
plicated intermittent claudication). Nevertheless, the observa-
tions in prospective studies that levels of several of these
circulating biomarkers predict progressive atherosclerosis in
the lower limb [31] suggest that these processes also contribute
to progression of chronic arterial occlusion. The associations
between VWF, ﬁbrin D-dimer or plasma viscosity with MI/
CHD deaths were attenuated after adjustment for CRP,
suggesting that the relationship between these variables and
CHD may reﬂect their association with the inﬂammatory
response. No independent associations of coagulation factors
(other than ﬁbrinogen), APTT or APC ratio were observed
with major CHD events.
Some conventional risk factors including systolic blood
pressure and HDL-cholesterol were important risk factors for
both MI/CHD death and angina in the present study, which is
consistent with previous reports [20,21]. In contrast, cigarette
smoking, prevalent diabetes and physical inactivity were only
associated with MI/CHD death in this cohort of older men
consistent with ﬁndings reported by The Womens Health
Initiative Observational Study of postmenopausal women [19].
Table 4 Adjusted hazards ratio (95% CI) of MI/CHD death and uncomplicated angina for a standard deviation increase in selected biomarkers
MI/CHD death Uncomplicated angina
*P-value for
equal associationModel 1 adjustment P-trend Model 1 + CRP P-trend Model 1 adjustment P-trend
SBP 1.27 (1.10, 1.47) 0.0004 1.30 (1.12, 1.50) 0.0002 1.15 (1.00, 1.27) 0.04 0.29
HDL-C 0.79 (0.68, 0.94) 0.006 0.84 (0.70, 0.99) 0.04 0.76 (0.65) 0.008 0.53
CRP 1.25 (1.09, 1.46) 0.002 – 0.92 (0.79, 1.07) 0.27 0.008
IL-6 1.23 (1.10, 1.46) 0.002 – 0.94 (0.81, 1.10) 0.45 0.02
Fibrinogen 1.21 (1.06, 1.37) 0.004 – 0.91 (0.78, 1.06) 0.17 0.007
VWF 1.19 (1.04, 1.37) 0.01 1.10 (0.97, 1.30) 0.13 0.98 (0.83, 1.10) 0.80 0.09
D-dimer 1.18 (1.02, 1.34) 0.02 1.11 (1.02, 1.31) 0.22 0.93 (0.80, 1.07) 0.34 0.05
Plasma viscosity 1.15 (1.01, 1.30) 0.03 1.05 (0.89, 1.23) 0.57 1.005 (0.87, 1.16) 0.93 0.25
Model 1 adjusted for social class, alcohol intake, BMI, prevalent stroke, smoking, physical activity, diabetes, systolic blood pressure and HDL-
Cholesterol. *P-value associated with the null hypothesis that the variable has the same association with MI/CHD death and uncomplicated angina
(model 1). P-value obtained by log-likelihood ratio tests. CHD, coronary heart disease; MI, myocardial infarction; VWF, von Willebrand factor.
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The strength and limitations of the present study require
careful consideration. The study is limited by its restriction
to predominantly white European men aged 60–79 years.
However, the study population is socially representative and
follow-up rates exceptionally high. Ascertainment of CHD
death and MI is based on standard methods and both CHD
mortality and MI incidence rates correspond closely with
national data [32]. The ascertainment of angina is based on the
presence of a clinical diagnosis, supplemented by investigations
where appropriate. The validity of this approach, as indicated
by its inﬂuence on future mortality and CHD incidence, has
been previously demonstrated [33]. All the cases deﬁned as
angina in the present analyses were uncomplicated by the
development of MI or CHD death, which would have been
identiﬁed by the follow-up methods used. Moreover, only a
very small proportion ( 2%) were admitted to hospital with
chest pain during the entire follow-up period, so it is likely that
almost all these men had chronic stable angina. Potential
circadian variation in the biomarkers may have inﬂuenced the
associations. However, adjustment for time of blood measure-
ment did not alter the ﬁndings.
We conclude that in older men, circulating biomarkers of
inﬂammation and hemostasis are related to incident MI/
CHD death but not to incident uncomplicated angina. These
ﬁndings support the potentially important roles of inﬂam-
mation and thrombotic tendency in pathogensis of acute
coronary syndromes and highlight the possible role for anti-
inﬂammatory or antithrombotic therapy for those who are at
high risk of MI/CHD death as indicated by their levels of
inﬂammatory and hemostatic variables. These ﬁndings also
have potential implications for prospective studies which use
composite measures of CHD combining angina and MI as
the endpoint when assessing the relationships between these
biomarkers and CHD risk particularly in older men. Further
prospective studies (and meta-analyses) are suggested to
establish with greater conﬁdence the speciﬁcity of these
associations for CHD (and CVD) events associated with
pathological or angiographic evidence of plaque rupture and
superadded thrombosis.
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